File

Report
2011-2012 AMCP
Pharmacy and Therapeutics
Competition
Ally Stojkoska
October 11th, 2011
Outline







Overview of the P&T Competition
Requirements for competing
Benefits of competing
2010-2011 Case Example
This year’s competition topic
Important dates and next meeting
Questions
What is P&T?
 P&T = Pharmacy and Therapeutics
 A committee that meets together to promote
safe, effective, and cost-effective drug
therapy
 Develop policies regarding drug evaluation,
selection, and utilization
 Educate practitioners on drugs and
appropriate drug utilization
Who utilizes P&T Committee?
 Any organization that maintains a drug
formulary utilizes a P&T Committee
 Hospitals
 Health Plans
 Prescription Benefit Managers (PBMs)
 VA and Military
What do P&T Committees do?
 Primarily physicians and pharmacists
 Includes practitioners from a variety of
specialties
 Review of scientific evidence and standards
or practice, peer reviewed medical
literature, clinical practice guidelines, and
pharmacoeconomic studies
 Manage the development and maintenance
of the organization’s drug formulary
Competition Requirements


Work in a team of four students
 Team request: you can choose ONE person who you
want to be in the same team with
 Must be an active AMCP member
Deliverables
 Evaluation of dossier / economic model and what
should be included using the Format v 2.1 or 3.0
 Analysis of manufacturer’s value argument and data
presented
 Evaluation advantages/disadvantages of this product
versus currently available formulations and place in
therapy
 Budget Impact Model
 Drug Monograph (maximum 15 pages)
Competition Requirements
 30 minute presentation and 30 minute Q&A
session with judges
 All materials must be submitted and
presentation completed to receive credit
Benefits
 Teamwork
 Organization
 Learn/Improve skills




Pharmacoeconomics
Clinical evaluation
Drug information
Presentation skills
More Benefits
 Networking opportunities
 Free food 
 THREE ELECTIVE CREDIT HOURS
 Enhance your CV/Resume
 Winning team gets expenses paid to the
2012 AMCP Showcase
 Compete at national competition
 OSU Teams were placed in TOP 3 twice
in the last six years!
 Challenge yourself!
National Competition
“Learning to work on a P&T committee through
AMCP’s P & T competition is a skill that will be very useful
in many pharmacist career pathways.”
Vinson Lee, University of Southern California 2006
Example Case 2010-2011
• At its next meeting, the Pitt Street
Health P&T Committee will conduct a
review of the place in therapy of the
antiplatelet drug prasugrel (Effient®).
▫
Specifically, the Committee will determine the formulary
status for a new chemical entity, prasugrel (Effient), an
antiplatelet medication indicated for the reduction of
atherothrombotic events (including stent thrombosis) in
acute coronary syndromes (ACS) in patients with unstable
angina (UA) or non-ST-segment elevation myocardial
infarction (NSTEMI) and ST-segment elevation myocardial
infarction (STEMI) who are managed with percutaneous
coronary intervention (PCI).
Example Case 2010-2011
Following your review of the dossiers and your own
independent research, the issue you must address is
whether there is sufficient evidence to support the
value of prasugrel (Effient®) for a change in status to
Preferred/Formulary. In other words, through
analysis of the dossier, model and your additional
research, should prasugrel be added to the formulary
or not and, if added, what will be the coverage
criteria?
Competition Requirements

Work in a team of four students
 Team request: you can choose ONE person who you want to
be in the same team with
 Must be an active AMCP member

Deliverables
 Evaluation of dossier / economic model and what should be
included using the Format v 2.1 or 3.0
 Analysis of manufacturer’s value argument and data
presented
 Evaluation advantages/disadvantages of this product versus
currently available formulations and place in therapy
 Budget Impact Model
 Drug Monograph (maximum 15 pages)
This year’s competition!
Dabigatran etexilate
(Pradaxa™)
Dabigatran etexilate (Pradaxa™)
Pradaxa™ is an anticoagulant indicated to
reduce the risk of stroke and systemic
embolism in patients with non-valvular
atrial fibrillation
 Direct thrombin inhibitor
 Lowers the risk of blood clots forming in
the body which may lead to strokes
Sign up for P&T Competition!
 Meet with your team regularly
 Try to work ahead of the schedule – You can start your
research on Dabigatran etexilate NOW!
 Do not downplay the importance of the written materials
 Only written material gets sent for national consideration
 Do not be afraid to ask for direction
 Faculty cannot give you direct answers, but may point you
in the right direction
Important Dates
 Team and individual sign-up
 Deadline: 10/21 Friday
 Email Vimal (reddy.108) or Felix (tran.250)
 Case and competition materials from previous
years will be distributed during P&T Sessions.
 Competition date: 4th week of Jan 2012
 National Competition date: April 2012
Next Meeting
October 25th, 2011
Questions???
Contact Vimal (reddy.108) or Felix (tran.250)

similar documents